Issue Date: November 18, 2013
Gene Silencing By Design
When new protein structures are reported, it’s often claimed they could lead to the design of therapeutic agents that interact with the proteins more effectively. A new study on short interfering RNAs (siRNAs) actually demonstrates such a result.
Last year, two research groups determined crystal structures of the human version of Argonaute—a protein in the RNA interference (RNAi) pathway that cells use to turn off target genes. siRNAs activate RNAi in cells by binding to . . .
To view the rest of this content, please log in with your ACS ID.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society